TheraNews Logo

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

globenewswire|2/18/2026|depression
Share this article:
Email

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

ONLY AVAILABLE IN PAID PLANS.


Originally reported by globenewswire. Read more

Share this article:
Email

Related Articles

More stories about depression